Background/Aims: Few studies of gene variants that affect estrogen activity investigate their association with age at onset of Alzheimer's disease (AD) in women of different ethnicities. We examined the influence of ESR1 polymorphisms on age at onset of AD in a multiethnic cohort of women. Methods: Among 1,436 women participating in the Washington Heights Inwood Columbia Aging Project, association with age at AD onset was assessed for 41 single-nucleotide polymorphisms (SNPs) on the ESR1 gene using Cox proportional hazard models, adjusting for presence of an APOE ε4 allele, years of education, and body mass index. Results: Six SNPs in self-identified White women were protectively associated with delayed age of AD onset in this self-identified group, including the two restriction fragment length polymorphisms Pvu II (rs2234693) and Xba I (rs9340799) (HR range = 0.420-0.483). Two separate SNPs were found to affect age of AD onset in self-identified Black women. Conclusions:ESR1 polymorphisms affect age of onset of AD in women, and risk alleles vary by ethnicity. These effects are possibly due to different linkage disequilibrium patterns or differences in comorbid environmental or cultural risk factors mediating the SNP effect on risk for AD.

1.
Shughrue PJ, Lane MV, Merchenthaler I: Comparative distribution of estrogen receptor-alpha and -beta mRNA in the rat central nervous system. J Comp Neurol 1997;388:507-525.
2.
McEwen BS: Invited review: estrogens effects on the brain: multiple sites and molecular mechanisms. J Appl Physiol 2001;91:2785-2801.
3.
Goodman Y, Bruce AJ, Cheng B, Mattson MP: Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid beta-peptide toxicity in hippocampal neurons. J Neurochem 1996;66:1836-1844.
4.
Toran-Allerand CD, Miranda RC, Bentham WD, Sohrabji F, Brown TJ, Hochberg RB, MacLusky NJ: Estrogen receptors colocalize with low-affinity nerve growth factor receptors in cholinergic neurons of the basal forebrain. Proc Natl Acad Sci USA 1992;89:4668-4672.
5.
Luine VN: Estradiol increases choline acetyltransferase activity in specific basal forebrain nuclei and projection areas of female rats. Exp Neurol 1985;89:484-490.
6.
Behl C, Widmann M, Trapp T, Holsboer F: 17-beta estradiol protects neurons from oxidative stress-induced cell death in vitro. Biochem Biophys Res Commun 1995;216:473-482.
7.
Jaffe AB, Toran-Allerand CD, Greengard P, Gandy SE: Estrogen regulates metabolism of Alzheimer amyloid beta precursor protein. J Biol Chem 1994;269:13065-13068.
8.
Gerhard M, Ganz P: How do we explain the clinical benefits of estrogen? From bedside to bench. Circulation 1995;92:5-8.
9.
Simoncini T, Mannella P, Genazzani AR: Rapid estrogen actions in the cardiovascular system. Ann NY Acad Sci 2006;1089:424-430.
10.
Brandi ML, Becherini L, Gennari L, Racchi M, Bianchetti A, Nacmias B, Sorbi S, Mecocci P, Senin U, Govoni S: Association of the estrogen receptor alpha gene polymorphisms with sporadic Alzheimer's disease. Biochem Biophys Res Commun 1999;265:335-338.
11.
Ji Y, Urakami K, Wada-Isoe K, Adachi Y, Nakashima K: Estrogen receptor gene polymorphisms in patients with Alzheimer's disease, vascular dementia and alcohol-associated dementia. Dement Geriatr Cogn Disord 2000;11:119-122.
12.
Maruyama H, Toji H, Harrington CR, Sasaki K, Izumi Y, Ohnuma T, Arai H, Yasuda M, Tanaka C, Emson PC, Nakamura S, Kawakami H: Lack of an association of estrogen receptor alpha gene polymorphisms and transcriptional activity with Alzheimer disease. Arch Neurol 2000;57:236-240.
13.
Lambert JC, Harris JM, Mann D, Lemmon H, Coates J, Cumming A, St-Clair D, Lendon C: Are the estrogen receptors involved in Alzheimer's disease? Neurosci Lett 2001;306:193-197.
14.
Lin GF, Ma QW, Zhang DS, Zha YL, Lou KJ, Shen JH: Polymorphism of alpha-estrogen receptor and aryl hydrocarbon receptor genes in dementia patients in Shanghai suburb. Acta Pharmacol Sin 2003;24:651-656.
15.
Usui C, Shibata N, Ohnuma T, Higashi S, Ohkubo T, Ueki A, Nagao M, Arai H: No genetic association between the myeloperoxidase gene -463 polymorphism and estrogen receptor-alpha gene polymorphisms and Japanese sporadic Alzheimer's disease. Dement Geriatr Cogn Disord 2006;21:296-299.
16.
Mattila KM, Axelman K, Rinne JO, Blomberg M, Lehtimaki T, Laippala P, Roytta M, Viitanen M, Wahlund L, Winblad B, Lannfelt L: Interaction between estrogen receptor 1 and the epsilon 4 allele of apolipoprotein E increases the risk of familial Alzheimer's disease in women. Neurosci Lett 2000;282:45-48.
17.
Porrello E, Monti MC, Sinforiani E, Cairati M, Guaita A, Montomoli C, Govoni S, Racchi M: Estrogen receptor alpha and APOE epsilon 4 polymorphisms interact to increase risk for sporadic AD in Italian females. Eur J Neurol 2006;13:639-644.
18.
Isoe-Wada K, Maeda M, Yong J, Adachi Y, Harada H, Urakami K, Nakashima K: Positive association between an estrogen receptor gene polymorphism and Parkinson's disease with dementia. Eur J Neurol 1999;6:431-435.
19.
Isoe K, Urakami K, Adachi Y, Nakashima K: Genetic association of estrogen receptor gene polymorphisms with Alzheimer's disease. Alzheimer's Res 1997;3:195-197.
20.
Monastero R, Cefalu AB, Camarda C, Noto D, Camarda LK, Caldarella R, Imbornone E, Averna MR, Camarda R: Association of estrogen receptor alpha gene with Alzheimer's disease: a case-control study. J Alzheimers Dis 2006;9:273-278.
21.
Ma SL, Tang NL, Tam CW, Lui VW, Lau ES, Zhang YP, Chiu HF, Lam LC: Polymorphisms of the estrogen receptor alpha (ESR1) gene and the risk of Alzheimer's disease in a southern Chinese community. Int Psychogeriatr 2009;21:977-986.
22.
Corbo RM, Gambina G, Ruggeri M, Scacchi R: Association of estrogen receptor alpha (ESR1) Pvu II and Xba I polymorphisms with sporadic Alzheimer's disease and their effect on apolipoprotein E concentrations. Dem Geriatr Cogn Disord 2006;22:67-72.
23.
Yaffe K, Lui LY, Grady D, Stone K, Morin P: Estrogen receptor 1 polymorphisms and risk of cognitive impairment in older women. Biol Psychiatry 2002;51:677-682.
24.
Tang MX, Cross P, Andrews H, Jacobs DM, Small S, Bell K, Merchant C, Lantigua R, Costa R, Stern Y, Mayeux R: Incidence of AD in African-Americans, Caribbean Hispanics, and Caucasians in northern Manhattan. Neurology 2001;56:49-56.
25.
Stern Y, Andrews H, Pittman J, Sano M, Tatemichi T, Lantigua R, Mayeux R: Diagnosis of dementia in a heterogeneous population. Development of a neuropsychological paradigm-based diagnosis of dementia and quantified correction for the effects of education. Arch Neurol 1992;49:453-460.
26.
Pritchard JK, Stephens M, Donnelly P: Inference of population structure using multilocus genotype data. Genetics 2000;155:945-959.
27.
Falush D, Stephens M, Pritchard JK: Inference of population structure using multilocus genotype data: linked loci and correlated allele frequencies. Genetics 2003;164:1567-1587.
28.
Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM: Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. ApoE and Alzheimer DiseaseMeta Analysis Consortium. JAMA 1997;278:1349-1356.
29.
Cauley JA, Gutai JP, Kuller LH, LeDonne D, Powell JG: The epidemiology of serum sex hormones in postmenopausal women. Am J Epidemiol 1989;129:1120-1131.
30.
Meldrum DR, Davidson BJ, Tataryn IV, Judd HL: Changes in circulating steroids with aging in postmenopausal women. Obstet Gynecol 1981;57:624-628.
31.
Judd HL, Shamonki IM, Frumar AM, Lagasse LD: Origin of serum estradiol in postmenopausal women. Obstet Gynecol 1982;59:680-686.
32.
Hixson JE, Vernier DT: Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31:545-548.
33.
Isoe K, Urakami K, Wakutani Y, Yong J, Adachi Y, Nakashima K: Screening for mutation of the presenilin 2 gene in Alzheimer's disease. Dement Geriatri Cogn Disord 1997;8:60.
34.
Ponglikitmongkol M, Green S, Chambon P: Genomic organization of the human oestrogen receptor gene. EMBO J 1988;7:3385-3388.
35.
Prince JA, Feuk L, Sawyer SL, Gottfries J, Ricksten A, Nagga K, Bogdanovic N, Blennow K, Brookes AJ: Lack of replication of association findings in complex disease: an analysis of 15 polymorphisms in prior candidate genes for sporadic Alzheimer's disease. Eur J Hum Genet 2001;9:437-444.
36.
Herrington DM, Howard TD, Brosnihan KB, McDonnell DP, Li X, Hawkins GA, Reboussin DM, Xu J, Zheng SL, Meyers DA, Bleecker ER: Common estrogen receptor polymorphism augments effects of hormone replacement therapy on E-selectin but not C-reactive protein. Circulation 2002;105:1879-1882.
37.
Schuit SC, de Jong FH, Stolk L, Koek WN, van Meurs JB, Schoofs MW, Zillikens MC, Hofman A, van Leeuwen JP, Pols HA, Uitterlinden AG: Estrogen receptor alpha gene polymorphisms are associated with estradiol levels in postmenopausal women. Eur J Endocrinol 2005;153:327-334.
38.
van Meurs JB, Schuit SC, Weel AE, van der Klift M, Bergink AP, Arp PP, Colin EM, Fang Y, Hofman A, van Duijn CM, van Leeuwen JP, Pols HA, Uitterlinden AG: Association of 5′ estrogen receptor alpha gene polymorphisms with bone mineral density, vertebral bone area and fracture risk. Hum Mol Genet 2003;12:1745-1754.
39.
Ioannidis JP, Ralston SH, Bennett ST, Brandi ML, Grinberg D, Karassa FB, Langdahl B, van Meurs JB, Mosekilde L, Scollen S, Albagha OM, Bustamante M, Carey AH, Dunning AM, Enjuanes A, van Leeuwen JP, Mavilia C, Masi L, McGuigan FE, Nogues X, Pols HA, Reid DM, Schuit SC, Sherlock RE, Uitterlinden AG: Differential genetic effects of ESR1 gene polymorphisms on osteoporosis outcomes. JAMA 2004;292:2105-2114.
40.
Schuit SC, Oei HH, Witteman JC, Geurts van Kessel CH, van Meurs JB, Nijhuis RL, van Leeuwen JP, de Jong FH, Zillikens MC, Hofman A, Pols HA, Uitterlinden AG: Estrogen receptor alpha gene polymorphisms and risk of myocardial infarction. JAMA 2004;291:2969-2977.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.